The Government approved capping trade margins on non-scheduled anti-cancer drugs at 30% of MRP; prices are expected to fall by up to 70%, saving patients about Rs 2,500 crore a year.
An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines, after which the National Pharmaceutical Pricing Authority (NPPA) will decide and notify the cap.
The cap covers branded and generic, domestic and imported, patented and non-patented cancer drugs; manufacturers must keep production at current levels.
NPPA found an average mark-up of about 170% on these drugs, reaching 700% or more in some cases.
It widens the February 2019 cap on 42 non-scheduled anti-cancer drugs under Paragraph 19 of DPCO 2013, which cut MRPs by up to 91% across 526 brands and saved Rs 984 crore a year.
Trade margin is the gap between the price at which a drug leaves the manufacturer (price to stockist) and the MRP paid by the patient. A 30%-of-MRP cap equals about a 43% mark-up on the stockist price. Scheduled (NLEM) drugs have ceiling prices; non-scheduled drugs did not.
Simple Analogy: A limit on how much the shop chain may add, not on the factory price.
| Aspect | February 2019 | October 2026 |
|---|---|---|
| Drugs covered | 42 selected non-scheduled anti-cancer drugs | Non-scheduled anti-cancer drugs on the DGHS committee's list |
| Cap | Trade margin of 30% | 30% of MRP |
| Price effect | MRPs cut by up to 91%, 526 brands | Up to 70% reduction expected |
| Annual saving | Rs 984 crore | About Rs 2,500 crore expected |
| Legal route | Paragraph 19, DPCO 2013 (extraordinary powers) | NPPA notification after the list is final |
Set up on 29 August 1997 by a Ministry of Chemicals and Fertilizers resolution as an attached office of the then Department of Chemicals and Petrochemicals (now Department of Pharmaceuticals). Fixes and revises ceiling prices, enforces DPCO 2013 and recovers overcharged amounts; exercises the Centre's DPCO powers, including Paragraph 19, under a May 2013 delegation order
Created on 1 July 2008 in the Ministry of Chemicals and Fertilizers to focus on the pharma sector, drug pricing and R&D; administers NPPA and the Jan Aushadhi scheme
Attached office of the Department of Health and Family Welfare, Ministry of Health and Family Welfare; gives technical advice on all medical and public health matters. Its expert committee will decide which cancer drugs are covered
Every Drugs (Prices Control) Order is issued under Section 3; overcharging is recovered with interest and penalty under the DPCO read with this Act
Replaced DPCO 1995. Schedule I = the National List of Essential Medicines, whose formulations get NPPA ceiling prices; non-scheduled drugs may raise MRP by at most 10% a year. Paragraph 19 lets the Government fix or revise the price of ANY drug in extraordinary circumstances in public interest
Released 13 September 2022 by the Health Ministry: 384 medicines (34 added, 26 dropped from the 376 of NLEM 2015), including four new anti-cancer drugs; substituted into DPCO Schedule I on 11 November 2022
Keep COVID-era devices affordable
Key: NPPA used Paragraph 19 to cap trade margin at 70% (price-to-distributor level) on pulse oximeters, BP monitors, nebulisers, digital thermometers and glucometers
Quality generic medicines at low prices
Key: Launched November 2008 by the Department of Pharmaceuticals as the Jan Aushadhi Campaign; renamed PMBJP in 2016; sells through Jan Aushadhi Kendras
Cut import cost of life-saving drugs
Key: 36 life-saving drugs, including cancer and rare-disease medicines, fully exempted from Basic Customs Duty; six more at a concessional 5%
NPPA set up
Department of Pharmaceuticals created
DPCO 2013 replaces DPCO 1995
30% trade margin cap on 42 non-scheduled anti-cancer drugs
70% trade margin cap on five medical devices
NLEM 2022 (384 medicines) released
30%-of-MRP cap approved for non-scheduled anti-cancer drugs
GS Paper 2 > Health > Access to Medicines; GS Paper 3 > Price Regulation
General Awareness > Government Policies > Health
General Awareness > Economy > Regulators
Drug listed in DPCO Schedule I (the NLEM), sold under an NPPA ceiling price
Drug outside the NLEM; MRP increase limited to 10% a year
Extraordinary power to fix the price of any drug in public interest
Difference between price to stockist and MRP